참고문헌 (20)

1. Ann Rheum Dis R Knevel 69 6 987 2010 10.1136/ard.2009.126748 Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, Landewe RB, Smolen JS, Sokka T, van der Heijde DM (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):987-994. doi: 10.1136/ard.2009.126748 

   상세보기

2. Arthritis Care Res (Hoboken) JA Singh 2012 Singh JA, Furst D, Saag KG (2012) 2012 update of the 2008 ACR recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of RA: reply to letter by Graudal et al. Arthritis Care Res (Hoboken). doi: 10.1002/acr.21872 

3. Mod Rheumatol R Koike 17 6 451 2007 10.3109/s10165-007-0626-3 Koike R, Takeuchi T, Eguchi K, Miyasaka N (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17(6):451-458. doi: 10.1007/s10165-007-0626-3 

   상세보기

4. Nat Rev Rheumatol T Takeuchi 6 11 644 2010 10.1038/nrrheum.2010.154 Takeuchi T, Kameda H (2010) The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 6(11):644-652. doi: 10.1038/nrrheum.2010.154 

   상세보기

5. Ann Rheum Dis T Takeuchi 67 2 189 2008 10.1136/ard.2007.072967 Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67(2):189-194. doi: 10.1136/ard.2007.072967 

   상세보기

6. J Rheumatol T Koike 36 5 898 2009 10.3899/jrheum.080791 Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M (2009) Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36(5):898-906. doi: 10.3899/jrheum.080791 

   상세보기

7. Mod Rheumatol T Koike 22 4 498 2012 10.3109/s10165-011-0541-5 Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Tanaka Y (2012) Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 22(4):498-508. doi: 10.1007/s10165-011-0541-5 

   상세보기

8. Arthritis Care Res (Hoboken) R Sakai 64 8 1125 2012 10.1002/acr.21666 Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M (2012) Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(8):1125-1134. doi: 10.1002/acr.21666 

   상세보기

9. Arthritis Rheum WG Dixon 54 8 2368 2006 10.1002/art.21978 Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54(8):2368-2376. doi: 10.1002/art.21978 

   상세보기

10. Ann Rheum Dis A Strangfeld 70 11 1914 2011 10.1136/ard.2011.151043 Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70(11):1914-1920. doi: 10.1136/ard.2011.151043 

    상세보기

11. Res Social Adm Pharm FS Lobo 2 1 143 2006 10.1016/j.sapharm.2005.12.001 Lobo FS, Wagner S, Gross CR, Schommer JC (2006) Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm 2(1):143-151. doi: 10.1016/j.sapharm.2005.12.001 

    상세보기

12. Ann Rheum Dis ML Hetland 67 7 1023 2008 10.1136/ard.2007.087262 Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, Ostergaard M, Tarp U (2008) Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 67(7):1023-1026. doi: 10.1136/ard.2007.087262 

    상세보기

13. ICH Steering Commitee. ICH harmonized tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting (1995). URL: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002749.pdf . Accessed 1 Nov 2013 

14. Arthritis Rheum J Listing 52 11 3403 2005 10.1002/art.21386 Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52(11):3403-3412. doi: 10.1002/art.21386 

    상세보기

15. Autoimmun Rev EG Favalli 8 3 266 2009 10.1016/j.autrev.2008.11.002 Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, Gorla R, Filippini M, Marchesoni A (2009) Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 8(3):266-273. doi: 10.1016/j.autrev.2008.11.002 

    상세보기

16. Arthritis Rheum KG Saag 59 6 762 2008 10.1002/art.23721 Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O’Dell J, Turkiewicz AM, Furst DE (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762-784. doi: 10.1002/art.23721 

    상세보기

17. Ann Rheum Dis JS Smolen 69 6 964 2010 10.1136/ard.2009.126532 Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975. doi: 10.1136/ard.2009.126532 

    상세보기

18. Japan College of Rheumatology (2012) 2012 Update of Japanese guideline for use of TNF inhibitors http://www.ryumachi-jp.com/info/guideline_TNF_120704.pdf of subordinate document. Accessed 1 Nov 2013 

19. Curr Opin Rheumatol H Castro-Rueda 20 3 314 2008 10.1097/BOR.0b013e3282f5fcf6 Castro-Rueda H, Kavanaugh A (2008) Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol 20(3):314-319. doi: 10.1097/BOR.0b013e3282f5fcf6 

    상세보기

20. Ann Rheum Dis K Au 70 5 785 2011 10.1136/ard.2010.128637 Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE (2011) High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70(5):785-791. doi: 10.1136/ard.2010.128637 

    상세보기